Valneva SE Total Assets
Valneva SE total assets. Based on the latest financial reports, Valneva SE (VLA) holds total assets worth €388.28 Million EUR (≈ $453.94 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see VLA company net worth for the company's overall valuation and market capitalisation.
Total Assets of Valneva SE (2005–2025)
Total assets of Valneva SE from 2005 to 2025. This chart illustrates how Valneva SE's total assets have evolved over time, based on quarterly financial data. See Valneva SE (VLA) share price today for real-time trading data and today's change.
Valneva SE - Asset Composition Analysis
Valneva SE Total Assets Breakdown (December 2025)
Valneva SE total assets breakdown as of December 2025. Valneva SE's total assets of €388.28 Million consist of 55.8% current assets and 44.2% non-current assets.
| Asset Category | Amount (EUR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 27.5% |
| Accounts Receivable | €27.81 Million | 7.0% |
| Inventory | €50.23 Million | 12.6% |
| Property, Plant & Equipment | €0.00 | 0.0% |
| Intangible Assets | €22.35 Million | 5.6% |
| Goodwill | €0.00 | 0.0% |
Asset Composition Trend (2005–2025)
This chart illustrates how Valneva SE's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Valneva SE short-term liquidity ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Valneva SE's current assets represent 55.8% of total assets in 2025, an increase from 48.5% in 2005.
- Cash Position: Cash and equivalents constituted 27.5% of total assets in 2025, up from 11.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, a decrease from 17.0% in 2005.
- Asset Diversification: The largest asset category is inventory at 12.6% of total assets.
Valneva SE Competitors by Total Assets
Key competitors of Valneva SE based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Valneva SE - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.16 | 2.27 | 1.59 |
| Quick Ratio | 1.69 | 1.77 | 1.25 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | €119.55 Million | €159.06 Million | €216.85 Million |
Valneva SE - Advanced Valuation Insights
This section examines the relationship between Valneva SE's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.61 |
| Latest Market Cap to Assets Ratio | 1.36 |
| Asset Growth Rate (YoY) | -20.2% |
| Total Assets | €398.84 Million |
| Market Capitalization | $543.87 Million USD |
Valuation Analysis
Above Book Valuation: The market values Valneva SE's assets above their book value (1.36x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Valneva SE's assets decreased by 20.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Valneva SE (2005–2025)
The table below shows the annual total assets of Valneva SE from 2005 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | €398.84 Million ≈ $466.28 Million |
-20.24% |
| 2024-12-31 | €500.03 Million ≈ $584.59 Million |
+8.69% |
| 2023-12-31 | €460.06 Million ≈ $537.86 Million |
-25.96% |
| 2022-12-31 | €621.34 Million ≈ $726.42 Million |
-23.98% |
| 2021-12-31 | €817.35 Million ≈ $955.57 Million |
+81.97% |
| 2020-12-31 | €449.16 Million ≈ $525.12 Million |
+69.67% |
| 2019-12-31 | €264.72 Million ≈ $309.49 Million |
+15.14% |
| 2018-12-31 | €229.91 Million ≈ $268.79 Million |
+21.42% |
| 2017-12-31 | €189.34 Million ≈ $221.36 Million |
-8.48% |
| 2016-12-31 | €206.88 Million ≈ $241.87 Million |
-24.82% |
| 2015-12-31 | €275.19 Million ≈ $321.72 Million |
+20.95% |
| 2014-12-31 | €227.52 Million ≈ $265.99 Million |
-10.56% |
| 2013-12-31 | €254.39 Million ≈ $297.41 Million |
+374.02% |
| 2012-12-31 | €53.67 Million ≈ $62.74 Million |
-26.57% |
| 2011-12-31 | €73.08 Million ≈ $85.44 Million |
-8.07% |
| 2010-12-31 | €79.50 Million ≈ $92.94 Million |
+73.00% |
| 2009-12-31 | €45.95 Million ≈ $53.73 Million |
+11.04% |
| 2008-12-31 | €41.38 Million ≈ $48.38 Million |
+4.55% |
| 2007-12-31 | €39.58 Million ≈ $46.28 Million |
+165.27% |
| 2006-12-31 | €14.92 Million ≈ $17.45 Million |
+2.20% |
| 2005-12-31 | €14.60 Million ≈ $17.07 Million |
-- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more